Company intelligence / Profile preview
Boston Pharmaceuticals
Cambridge, Massachusetts, United Statesbostonpharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~72
- Development stage
- Other
01
Overview
Boston Pharmaceuticals’ lead program, efimosfermin alfa—a long-acting FGF21 analogue—has demonstrated positive Phase 2 results in patients with F2/F3 MASH. The drug has shown potential to reverse liver fibrosis and halt progression of MASH. GSK has agreed to acquire this asset for further development into Phase 3 and beyond.
- Therapeutic areas
- GastroenterologyMetabolic Disorders
- Modalities
- Small moleculeProteinBiologic
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
GSK – acquisition of efimosfermin alfaNovartis – original licensor of efimosfermin alfa
Beyond the preview
Go deeper on Boston Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Boston Pharmaceuticals.